Ouyang Weiming, Zhang Dongyun, Li Jingxia, Verma Udit N, Costa Max, Huang Chuanshu
Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York, USA.
J Cell Physiol. 2009 Jan;218(1):205-14. doi: 10.1002/jcp.21590.
It is well-known that insoluble nickel compounds possess much more potent carcinogenic activities as compared with soluble nickel compounds. Although it is assumed that the different entry and clearance rate are responsible for the difference, the mechanisms underlying the different carcinogenic activities are still not well understood yet. In the present study, we found that exposure to soluble, but not insoluble nickel compounds, caused a significant inhibition of cell growth and G1/G0 cell cycle arrest, which was concomitant with a marked down-regulation of cylin D1, an essential nuclear protein for controlling G1/S transition, while both soluble and insoluble nickel compounds showed similar effects on NFkappaB activation, HIF-1alpha protein accumulation and TNF-alpha transcription and CAP43 protein expression at same doses range. The down-regulation of cyclin D1 is due to protein degradation rather than inhibition of transcription, because the nickel compounds treatment did not change cyclin D1 mRNA level, while MG132, the proteasome inhibitor, can rescue the degradation of cyclin D1 caused by soluble nickel compound. Moreover, the soluble nickel-induced cyclin D1 degradation is dependent on its Thr286 residue and requires IKKalpha, but not HIF-1alpha, which are both reported to be involved in cyclin D1 down-regulation. Taken together, we demonstrate that soluble, but not insoluble nickel compound, is able to cause cyclin D1 degradation and a cell growth arrest in an IKKalpha-dependent manner. Given the role of cyclin D1 and cell proliferation in carcinogenesis, we anticipate that the different effects of soluble and insoluble nickel compounds on cyclin D1 degradation and cell growth arrest may at least partially account for their different carcinogenic activities.
众所周知,与可溶性镍化合物相比,不溶性镍化合物具有更强的致癌活性。尽管人们认为不同的摄入和清除率是造成这种差异的原因,但不同致癌活性背后的机制仍未得到很好的理解。在本研究中,我们发现,暴露于可溶性而非不溶性镍化合物会导致细胞生长显著抑制和G1/G0细胞周期停滞,这与细胞周期蛋白D1(一种控制G1/S转换的必需核蛋白)的显著下调同时发生,而在相同剂量范围内,可溶性和不溶性镍化合物对NFκB激活、HIF-1α蛋白积累、TNF-α转录和CAP43蛋白表达显示出相似的影响。细胞周期蛋白D1的下调是由于蛋白质降解而非转录抑制,因为镍化合物处理并未改变细胞周期蛋白D1的mRNA水平,而蛋白酶体抑制剂MG132可以挽救可溶性镍化合物引起的细胞周期蛋白D1的降解。此外,可溶性镍诱导的细胞周期蛋白D1降解依赖于其苏氨酸286残基,并且需要IKKα,但不需要HIF-1α,据报道这两者都参与细胞周期蛋白D1的下调。综上所述,我们证明可溶性而非不溶性镍化合物能够以IKKα依赖的方式导致细胞周期蛋白D1降解和细胞生长停滞。鉴于细胞周期蛋白D1和细胞增殖在致癌过程中的作用,我们预计可溶性和不溶性镍化合物对细胞周期蛋白D1降解和细胞生长停滞的不同影响可能至少部分解释了它们不同的致癌活性。